XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Income Statement
NASDAQ:XERS - Nasdaq - US98422E1038 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 222.55M | 203.07M | 163.91M | 110.20M | 49.60M | |||
| Cost Of Goods | 39.59M | 36.83M | 28.64M | 22.60M | 13.30M | |||
| Gross Profit | 182.96M | 166.24M | 135.27M | 87.60M | 36.30M | |||
| Operating Expenses | 205.45M | 199.88M | 179.28M | 159.50M | 142.70M | |||
| Research and Development | 25.49M | 25.56M | 22.34M | 21.00M | 24.90M | |||
| Selling, General, and Administrative Expenses | 169.12M | 163.48M | 146.09M | 127.60M | 117.30M | |||
| Operating Income | -22.49M | -33.65M | -44.01M | -71.80M | -106.50M | |||
| Interest Income/Expense | -26.18M | -25.16M | -21.86M | -11.50M | -6.90M | |||
| Other Income/Expense | 1.02M | 4.40M | 5.20M | -1.40M | -700.00K | |||
| Non Recurring Items | 0.00 | -2.69M | -2.84M | -11.30M | -8.70M | |||
| Income Before Taxes | -47.65M | -57.10M | -63.50M | -96.10M | -122.70M | |||
| Income Tax | -2.58M | -2.27M | -1.25M | -1.40M | 0.00 | |||
| Net Income | -45.08M | -54.84M | -62.26M | -94.70M | -122.70M | |||
| EBITDA | -9.76M | -21.02M | -30.85M | -59.56M | -104.62M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.30 | -0.37 | -0.45 | -0.70 | -1.55 | |||
| Non GAAP EPS | -0.30 | -0.38 | -0.45 | -0.70 | -1.52 | |||
| Statistics | ||||||||
| Gross Profit Margin | 82.21% | 81.86% | 82.52% | 79.49% | 73.19% | |||
| Profit Margin | -20.25% | -27.00% | -37.98% | -85.93% | -247.38% | |||
| Operating Profit Margin | -10.11% | -16.57% | -26.85% | -65.15% | -214.72% | |||
All data in USD